AI
IOVA icon

Analytic Investors’s Iovance Biotherapeutics IOVA Stock Holding History

Analytic Investors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,313
Closed -$71K – 652
2015
Q3 		$71K Buy
+12,313
New +$95.9K ﹤0.01% 541

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Analytic Investors's IOVA Position: Q4 2015 in Review

Analytic Investors sold out of Iovance Biotherapeutics (IOVA) in Q4 2015, closing a stake of 12,313 shares — an estimated $71K sold.

Analytic Investors first reported a position in IOVA in Q3 2015 and held it in 1 quarter. The position peaked at $71K in Q3 2015. 82 funds tracked by Wall St. Rank hold IOVA as of Q4 2015.

  • Analytic Investors reported no remaining Iovance Biotherapeutics position as of Q4 2015 after selling out during the quarter.
  • Analytic Investors sold 12,313 Iovance Biotherapeutics shares in Q4 2015, an estimated $71K.
  • Analytic Investors first reported a position in Iovance Biotherapeutics in Q3 2015 and held it in 1 quarter.
  • Analytic Investors's Iovance Biotherapeutics position peaked at $71K in Q3 2015.
  • 82 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2015.

Based on Analytic Investors's 13F filing for Q4 2015, filed 12 Feb 2016.